The MEK1/2 inhibitor trametinib increases progression-free survival from 7.2 months to 13 months in women with recurrent low-grade serous ovarian cancer. The drug also boosts the overall response rate from 6% to 26%.

©2022 American Association for Cancer Research.
2022
American Association for Cancer Research.
You do not currently have access to this content.